Agrypnia and Paranasal sinus hypersecretion
Paranasal sinus hypersecretion is found among people with Agrypnia, especially for people who are female, 60+ old.
The study analyzes which people have Paranasal sinus hypersecretion with Agrypnia. It is created by eHealthMe based on reports of 32 people who have Agrypnia from the Food and Drug Administration (FDA), and is updated regularly. You can use the study as a second opinion to make health care decisions.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
32 people who have Agrypnia and Paranasal Sinus Hypersecretion are studied.
What is Agrypnia?
Agrypnia is found to be associated with 4,606 drugs and 5,092 conditions by eHealthMe.
What is Paranasal sinus hypersecretion?
Paranasal sinus hypersecretion is found to be associated with 729 drugs and 394 conditions by eHealthMe.
Number of Paranasal sinus hypersecretion in Agrypnia reports submitted per year:
Gender of people who have Agrypnia and experienced Paranasal Sinus Hypersecretion *:
- female: 81.25 %
- male: 18.75 %
Age of people who have Agrypnia and experienced Paranasal Sinus Hypersecretion *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 0.0 %
- 30-39: 13.64 %
- 40-49: 18.18 %
- 50-59: 27.27 %
- 60+: 40.91 %
Common co-existing conditions for these people *:
- High Blood Pressure: 11 people, 34.38%
- Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 11 people, 34.38%
- Pain: 9 people, 28.12%
- Stress And Anxiety: 9 people, 28.12%
- Depression: 9 people, 28.12%
- High Blood Cholesterol: 9 people, 28.12%
- Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 8 people, 25.00%
- Diabetes: 7 people, 21.88%
- Neuropathy Peripheral (surface nerve damage): 7 people, 21.88%
- Crohn's Disease (condition that causes inflammation of the gastrointestinal tract): 7 people, 21.88%
Common drugs taken by these people *:
- Humira: 21 people, 65.62%
- Methotrexate: 10 people, 31.25%
- Folic Acid: 8 people, 25.00%
- Ambien: 7 people, 21.88%
- Aspirin: 5 people, 15.62%
- Cymbalta: 5 people, 15.62%
- Multivitamin: 5 people, 15.62%
- Xanax: 5 people, 15.62%
- Amlodipine: 4 people, 12.50%
- Prednisone: 4 people, 12.50%
Common symptoms for these people *:
- Cough: 15 people, 46.88%
- Nasopharyngitis (inflammation of the nasopharynx): 7 people, 21.88%
- Sinus Disorder (disease of sinus): 7 people, 21.88%
- Irritable Bowel Syndrome: 6 people, 18.75%
- Joint Pain: 6 people, 18.75%
- Pain: 6 people, 18.75%
- Drug Ineffective: 5 people, 15.62%
- Injection Site Pain: 5 people, 15.62%
- Fever: 4 people, 12.50%
- Fatigue (feeling of tiredness): 4 people, 12.50%
* Approximation only. Some reports may have incomplete information.
Do you take medications and have Paranasal sinus hypersecretion?Check whether Paranasal sinus hypersecretion is associated with a drug or a condition
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Treatments, associated drugs and conditions:
COVID vaccines that are related to Paranasal sinus hypersecretion:
- Paranasal sinus hypersecretion in Moderna COVID Vaccine
- Paranasal sinus hypersecretion in Pfizer BioNTech Covid Vaccine
- Paranasal sinus hypersecretion in Johnson and Johnson Covid Vaccine
Common drugs associated with Paranasal sinus hypersecretion:
All the drugs that are associated with Paranasal sinus hypersecretion:
- Paranasal sinus hypersecretion (729 drugs)
Common conditions associated with Paranasal sinus hypersecretion:
All the conditions that are associated with Paranasal sinus hypersecretion:
- Paranasal sinus hypersecretion (394 conditions)
How the study uses the data?
The study is based on Paranasal sinus hypersecretion and Agrypnia, and their synonyms.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Aspirin and Muscle Aches - 5 seconds ago
- Copegus and Dizziness - 15 seconds ago
- Azithromycin and Nephrotic Syndrome - 19 seconds ago
- Solifenacin Succinate and Tinnitus - 34 seconds ago
- Hydromorphone Hydrochloride and Lioresal drug interaction - 44 seconds ago
- Coumadin and Fulvestrant drug interaction - a minute ago
- Warfarin Sodium and Ranitidine drug interaction - a minute ago
- Lump In The Abdomen and drugs of ingredients of buspirone hydrochloride - a minute ago
- Cosentyx and Neuralgia - a minute ago
- Gemcitabine and Arthritis - a minute ago